Baird lowered the firm’s price target on Alto Neuroscience (ANRO) to $36 from $38 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANRO:
- Alto Neuroscience price target raised to $24 from $21 at Wedbush
- Alto Neuroscience: Buy Rating Reiterated as Lead Asset Advances and Cash Runway Extends; $28 Price Target Maintained
- Ritu Baral Reiterates Buy on Alto Neuroscience, Citing Pivotal ALTO-207 Phase 2b Trial in TRD and Strong Cash Runway Through 2029
- Alto Neuroscience Shareholders Shape Governance and Equity Plans
- Alto Neuroscience reports Q1 EPS (80c) vs (56c) last year